Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Retained Earnings of $4.2 billion for Q2 2026, down 47.65% year-over-year from $8.0 billion in Q2 2025, and down 7.88% quarter-over-quarter from $4.5 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Retained Earnings history runs 10 years deep, the most recent figure standing at $4.2 billion for Q2 2026.
- In Q2 2026, Retained Earnings fell 47.65% year-over-year to $4.2 billion; the TTM figure through Jun 2026 stood at $4.2 billion (down 47.65% YoY), while the FY2026 annual figure was $4.7 billion, down 39.3% from the prior year.
- Retained Earnings for Q2 2026 stood at $4.2 billion, down from $4.5 billion in the prior quarter.
- The five-year high for Retained Earnings was $12.7 billion in Q1 2022, with the low at $4.2 billion in Q2 2026.
- The 5-year median for Retained Earnings is $9.4 billion (2024), against an average of $9.0 billion.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings dropped 3.67% in 2023, then slumped 47.65% in 2026.
- Takeda Pharmaceutical's Retained Earnings stood at $10.7 billion in 2022, then dropped by 11.45% to $9.4 billion in 2023, then dropped by 10.14% to $8.5 billion in 2024, then decreased by 16.16% to $7.1 billion in 2025, then tumbled by 41.22% to $4.2 billion in 2026.
- Business Quant data shows TAK's Retained Earnings at $4.2 billion in Q2 2026, $4.5 billion in Q1 2026, and $7.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 3.75 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | -800.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.18 Bn |
| Mar 31, 2026 | 4.54 Bn |
| Dec 31, 2025 | 7.12 Bn |
| Sep 30, 2025 | 7.80 Bn |
| Jun 30, 2025 | 7.99 Bn |
| Mar 31, 2025 | 7.78 Bn |
| Dec 31, 2024 | 8.49 Bn |
| Jun 30, 2024 | 8.60 Bn |
| Mar 31, 2024 | 9.39 Bn |
| Dec 31, 2023 | 9.45 Bn |
| Sep 30, 2023 | 10.01 Bn |
| Jun 30, 2023 | 10.87 Bn |
| Mar 31, 2023 | 11.65 Bn |
| Dec 31, 2022 | 10.67 Bn |
| Sep 30, 2022 | 11.08 Bn |
| Jun 30, 2022 | 11.29 Bn |
| Mar 31, 2022 | 12.73 Bn |
| Dec 31, 2021 | 12.90 Bn |
| Sep 30, 2021 | 14.09 Bn |
| Jun 30, 2021 | 14.31 Bn |